MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 21, 2020 | Series E | ¥700M | 1 | — | — | Detail |
Aug 5, 2020 | Series D | ¥300M | 1 | — | — | Detail |
Sep 26, 2016 | Series C | $55M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Zhongtai Venture Capital | — | Series E |
Sinopharm-CICC | — | Series D |
GP TMT Capital | — | Series C |